Cargando…

Correction: A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers

Detalles Bibliográficos
Autores principales:	Winter, Jordan M., Tang, Laura H., Klimstra, David S., Brennan, Murray F., Brody, Jonathan R., Rocha, Flavio G., Jia, Xiaoyu, Qin, Li-Xuan, D’Angelica, Michael I., DeMatteo, Ronald P., Fong, Yuman, Jarnagin, William R., O’Reilly, Eileen M., Allen, Peter J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414547/ http://dx.doi.org/10.1371/annotation/2533f354-bbec-404a-9661-2c052963b918

Ejemplares similares

A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers
por: Winter, Jordan M., et al.
Publicado: (2012)

Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract
por: Miller, George, et al.
Publicado: (2009)

Hepatic Parenchymal Preservation Surgery: Decreasing Morbidity and Mortality Rates in 4,152 Resections for Malignancy
por: Kingham, T Peter, et al.
Publicado: (2014)

The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma
por: Rose, J. Bart, et al.
Publicado: (2016)

Gene Expression Profiles Accurately Predict Outcome Following Liver Resection in Patients with Metastatic Colorectal Cancer
por: Ito, Hiromichi, et al.
Publicado: (2013)

Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing
por: Zheng, Jian, et al.
Publicado: (2018)

Do mesothelin/MUC16 interactions facilitate adenocarcinoma metastases to intracranial meningiomas?
por: Johnson, Mahlon D.
Publicado: (2016)

Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma
por: Correa-Gallego, Camilo, et al.
Publicado: (2016)

Isolated Hepatic Splenosis: First Reported Case
por: D'Angelica, Michael, et al.
Publicado: (1998)

Combined Ablation and Resection (CARe) as an Effective Parenchymal Sparing Treatment for Extensive Colorectal Liver Metastases
por: Evrard, Serge, et al.
Publicado: (2014)

Recognition of Intrabiliary Hepatic Metastases From Colorectal Adenocarcinoma
por: Povoski, Stephen P., et al.
Publicado: (2000)

Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
por: Weidemann, Sören, et al.
Publicado: (2021)

Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes
por: Sadot, Eran, et al.
Publicado: (2015)

Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel
por: Ali, Asif, et al.
Publicado: (2014)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
por: Gubbels, Jennifer AA, et al.
Publicado: (2006)

Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation
por: Chen, Shih-Hsun, et al.
Publicado: (2013)

Long-term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma
por: Malleo, Giuseppe, et al.
Publicado: (2021)

Safe and Successful Yttrium-90 Resin Microsphere Radioembolization in a Heavily Pretreated Patient with Chemorefractory Colorectal Liver Metastases after Biliary Stent Placement above the Papilla
por: Sotirchos, Vlasios S., et al.
Publicado: (2014)

Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
por: Einama, Takahiro, et al.
Publicado: (2021)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane
por: Su, Yang, et al.
Publicado: (2016)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
por: Faust, Joshua R., et al.
Publicado: (2022)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin
por: Lurie, Eugene, et al.
Publicado: (2020)

Characterization of human mesothelin transcripts in ovarian and pancreatic cancer
por: Muminova, Zhanat E, et al.
Publicado: (2004)

Near infrared photoimmunotherapy with an anti-mesothelin antibody
por: Nagaya, Tadanobu, et al.
Publicado: (2016)

The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
por: Hilliard, Tyvette S.
Publicado: (2018)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

mucG, mucH, and mucI Modulate Production of Mutanocyclin and Reutericyclins in Streptococcus mutans B04Sm5
por: Baker, Jonathon L., et al.
Publicado: (2022)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_74c0oh46eh3g2jb1nfrr4spqk8